Diroximel Fumarate Patent Expiration
Diroximel Fumarate is Used for treating multiple sclerosis. It was first introduced by Biogen Inc
Diroximel Fumarate Patents
Given below is the list of patents protecting Diroximel Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vumerity | US10080733 | Prodrugs of fumarates and their use in treating various diseases | Sep 20, 2033 | Biogen Inc |
| Vumerity | US8669281 | Prodrugs of fumarates and their use in treating various diseases | Sep 20, 2033 | Biogen Inc |
| Vumerity | US9090558 | Prodrugs of fumarates and their use in treating various diseases | Sep 20, 2033 | Biogen Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Diroximel Fumarate's patents.
Latest Legal Activities on Diroximel Fumarate's Patents
Given below is the list recent legal activities going on the following patents of Diroximel Fumarate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Resp. to req. for info. sent under 37 CFR 1.750 | 03 Jun, 2024 | US8669281 |
| Withdrawal of Application for PTE Critical | 01 May, 2024 | US9090558 |
| Withdrawal of Application for PTE Critical | 01 May, 2024 | US10080733 |
| Requirement for information sent under 37 CFR 1.750 | 04 Apr, 2024 | US10080733 |
| Requirement for information sent under 37 CFR 1.750 | 04 Apr, 2024 | US9090558 |
| Requirement for information sent under 37 CFR 1.750 | 04 Apr, 2024 | US8669281 |
| Notice of Final Determination -Election Required | 29 Mar, 2024 | US10080733 |
| Notice of Final Determination -Election Required | 29 Mar, 2024 | US8669281 |
| Notice of Final Determination -Election Required | 29 Mar, 2024 | US9090558 |
| FDA Final Eligibility Letter Critical | 26 Apr, 2023 | US10080733 |
Diroximel Fumarate's Family Patents
